Mycophenolate
Overview
Mycophenolate is an immunosupressant, first isolated in 1898 from Penicillium stoloniferum. Mycophenolate is a reversible inhibitor of inosine monophosphate dehydrogenase and thus inhibits purine synthesis, with potent cytostatic effects on both T-and B-lymphocytes. Mycophenolate is used in combination with other immunosupressants, for the treatment and prevention of graft rejection and in auto-immune or immune-mediate inflammatory disease. it was approved by the FDA in May 3, 1995, for prevention of alograft rejection.
Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA), belongs to a class of medications known as immunosuppressives. inosine monophosphate dehydrogenase (IMPDH) inhibitor. This medication was used originally in the management of patients with organ transplants, but is now recommended in the treatment of some autoimmune diseases.
Categories
- 8 Antineoplastics, immunomodulators and drugs used in palliative care
Primary Characterstics
Indications
Back to top
Pharmacokinetics
Back to top
Contraindications
Back to top
Drug Interactions
Mycophenolate is known to interact with other drugs, the details of drug interactions is as follows:
Severity N/A
Cholestyramine Interaction of Cholestyramine with Mycophenolate
Details: Concurrent use decrease the AUC approximately 40%.
Interaction of Magnesium Oxides and Hydroxides with Mycophenolate
Details: Concurrent use decrease the absorption of mycophenolate.
Interaction of Rifampicin with Mycophenolate
Sevelamer HCl Interaction of Sevelamer HCl with Mycophenolate
Details: Reduced level of mycophenolate is observed when co-administered with sevelamer HCl
Management: close monitoring of blood concentrations should be considered during the use of combination and after its withdrawal.
These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Back to top
Side Effects
Back to top
Dosage
Mycophenolate's dosage details are as follows:
| Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
| 1 g | 1 (1) | 12 hourly | PO | Starting within 72 hrs of transplantation. |
Paedriatic Dosage (20kg)
|
| No data regarding the Paedriatic dosage details of Mycophenolate is available. |
Neonatal Dosage (3kg)
|
| No data regarding the neonatal dosage details of Mycophenolate is available. |
High Risk Groups
Drug should not be given to Pregnant Mothers, and patients suffering from Kidney dysfunction.
If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Back to top
Warning / Precautions
Back to top
Storage Conditions
Back to top
Interference in Pathology
Back to top
Brands / Trade Names of
Mycophenolate
Back to top
Previous Drug Generic - Next Drug Generic